Literature DB >> 28714409

AMPK: Therapeutic Target for Diabetes and Cancer Prevention.

Shotaro Umezawa1, Takuma Higurashi1, Atsushi Nakajima1.   

Abstract

BACKGROUND: AMP-activated protein kinase (AMPK) is a protein kinase that maintains homeostasis in cells and organs. As a master regulator of metabolism, AMPK coordinates many metabolic reactions. AMPK is a key factor in diabetes and metabolic syndrome associated with dysregulation of the metabolic status. Recently, AMPK has also attracted attention as a tumor suppressor. The aim of this article is to discuss about the role of AMPK in diabetes as well as cancer and to evaluate its effectiveness in treatment and prevention of these diseases.
METHOD: We reviewed studies of signaling mechanism involving AMPK and research on the role of AMPK in human disease including diabetes and cancer. In particular, we focused our attention on clinical trials about cancer treatment and prevention targeting AMPK.
RESULTS: Many experimental studies reported the relation of AMPK and various metabolic reactions, mainly regulating energy homeostasis. Recent studies showed effect of AMPK on arrest of cell cycle as well as suppression of inflammation, which are important factors for carcinogenesis. Although some clinical studies investigated cancer treatment and prevention targeting AMPK, the effective yields in clinical trial have been limited.
CONCLUSION: AMPK activation as represented by metformin showed to improve disorders associated with diabetes and metabolic syndrome and became a well-established treatment strategy for these diseases. The increasing evidence suggests that AMPK is a promising target in the treatment and prevention of cancer. Further investigation including long-term clinical trials with large sample size is needed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  AMPK; biguanide; cancer; chemoprevention; diabetes; metabolic syndrome; metformin

Mesh:

Substances:

Year:  2017        PMID: 28714409     DOI: 10.2174/0929867324666170713150440

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  14 in total

Review 1.  Crosstalk between the mTOR and DNA Damage Response Pathways in Fission Yeast.

Authors:  John-Patrick Alao; Luc Legon; Charalampos Rallis
Journal:  Cells       Date:  2021-02-02       Impact factor: 6.600

2.  The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models.

Authors:  Clara Lemos; Volker K Schulze; Simon J Baumgart; Ekaterina Nevedomskaya; Tobias Heinrich; Julien Lefranc; Benjamin Bader; Clara D Christ; Hans Briem; Lara P Kuhnke; Simon J Holton; Ulf Bömer; Philip Lienau; Franz von Nussbaum; Carl F Nising; Marcus Bauser; Andrea Hägebarth; Dominik Mumberg; Bernard Haendler
Journal:  Cell Oncol (Dordr)       Date:  2021-01-25       Impact factor: 6.730

3.  Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer.

Authors:  Xiao Lu; Dong Zhou; Bing Hou; Quan-Xing Liu; Qian Chen; Xu-Feng Deng; Zu-Bin Yu; Ji-Gang Dai; Hong Zheng
Journal:  Cancer Manag Res       Date:  2018-05-16       Impact factor: 3.989

Review 4.  Cancer Biology and Prevention in Diabetes.

Authors:  Swayam Prakash Srivastava; Julie E Goodwin
Journal:  Cells       Date:  2020-06-02       Impact factor: 6.600

Review 5.  Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.

Authors:  Tamás Nagy; Viktória Fisi; Dorottya Frank; Emese Kátai; Zsófia Nagy; Attila Miseta
Journal:  Cells       Date:  2019-08-28       Impact factor: 6.600

6.  Protective Effects and Mechanisms of Vaccarin on Vascular Endothelial Dysfunction in Diabetic Angiopathy.

Authors:  Fei Xu; Yixiao Liu; Xuexue Zhu; Shuangshuang Li; Xuelin Shi; Zhongjie Li; Min Ai; Jiangnan Sun; Bao Hou; Weiwei Cai; Haijian Sun; Lulu Ni; Yuetao Zhou; Liying Qiu
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

Review 7.  The Effects of Resveratrol in the Treatment of Metabolic Syndrome.

Authors:  Chih-Yao Hou; You-Lin Tain; Hong-Ren Yu; Li-Tung Huang
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

Review 8.  Peroxisome Proliferator-Activated Receptors and Caloric Restriction-Common Pathways Affecting Metabolism, Health, and Longevity.

Authors:  Kalina Duszka; András Gregor; Hervé Guillou; Jürgen König; Walter Wahli
Journal:  Cells       Date:  2020-07-16       Impact factor: 6.600

9.  Metformin use in cancer survivors with diabetes reduces all-cause mortality, based on the Korean National Health Insurance Service between 2002 and 2015.

Authors:  Joungyoun Kim; Yoon-Jong Bae; Jae-Woo Lee; Ye-Seul Kim; Yonghwan Kim; Hyo-Sun You; Hyeong-Seop Kim; Eun-A Choi; Ye-Eun Han; Hee-Taik Kang
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

10.  Metformin coordinates osteoblast/osteoclast differentiation associated with ischemic osteonecrosis.

Authors:  See-Hyoung Park; Mi-Ae Kang; Young Jae Moon; Kyu Yun Jang; Jung Ryul Kim
Journal:  Aging (Albany NY)       Date:  2020-02-11       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.